COMPANY

Asklepion Pharmaceuticals

HQ: Baltimore, MD source · asklepionpharm.com ↗ · Mid-Atlantic

Asklepion is focused on the discovery, development, and commercialization of pharmaceutical products to help patients who have little to no therapeutic options, due to the rarity of their conditions. From company website Source · Oct 12, 2026

Keywords: Ventricular Septal Defect Atrioventricular Septal Defect Sickle Cell Disease Primum Atrial Septal Defect Acute Vaso Occlusive Crisis (VOC) Acute Lung Injury Acute Hypoxemic Respiratory Failure Atrial Septal Defect Congenital Heart Defects Pulmonary Hypertension L-citrulline

Location: Baltimore, MD · source · Oct 14, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

Jul 25, 2025 Trial start Phase 3: A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis source ↗
Jun 29, 2022 Trial start Phase 3: A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing S source ↗
Apr 29, 2021 Trial start Phase 1/Phase 2: L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC) source ↗
Oct 15, 2020 Trial start Phase 2: Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 source ↗
2016-08 Trial start Phase 3: L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects source ↗
2010-09 Trial start Phase 1/Phase 2: Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol source ↗
2006-05 Trial start Phase 3: Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery source ↗

Upcoming milestones

2027-06 (ESTIMATED) · Phase 3 · A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis · NCT06989567

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT06989567	A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis	Phase 3	Not yet recruiting	Jul 25, 2025	2027-06 (estimated)
NCT05253209	A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects	Phase 3	Terminated	Jun 29, 2022	May 10, 2024 (actual)
NCT04852172	L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)	Phase 1/Phase 2	Terminated	Apr 29, 2021	Feb 29, 2024 (actual)
NCT02891837	L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects	Phase 3	Completed	2016-08	2019-06 (actual)
NCT04570384	Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19	Phase 2	Completed	Oct 15, 2020	Aug 30, 2021 (actual)
NCT01120964	Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol	Phase 1/Phase 2	Completed	2010-09	2012-04 (actual)
NCT00335244	Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery	Phase 3	Completed	2006-05	2009-12 (actual)